background and purpose: patients with non-transfusion-dependent beta thalassemia major (ntdtm) could reach old age, marry and have children with appropriate care. this study aimed to review the marital status and maternal-fetal outcomes of ntdtm patients at thalassemia research center (trc) of sari, iran. methods: in this study, medical records of patients with β-thalassemia major were reviewed...

background: transfusion is the mainstay treatment of patients with thalassemia major and occasionally in thalassemia intermediate. alloimmunization is an unwanted side effect of blood transfusion. the present study intended to determine the frequency of alloimmunization in patients with β- thalassemia major and thalassemia intermediate in southwest iran. patients and methods: this was a cross-s...

Background: Transfusion is the mainstay treatment of patients with thalassemia major and occasionally in thalassemia intermediate. Alloimmunization is an unwanted side effect of blood transfusion. The present study intended to determine the frequency of alloimmunization in patients with β- thalassemia major and thalassemia intermediate in Southwest Iran. Patients and Methods: This was a cross-...

background and purpose: despite extensive research on family planning and education, reproductive behavior of high-risk couples for thalassemia remains a major concern among medical professionals. this study aimed to evaluate the knowledge and attitude of carrier couples for transfusion-dependent thalassemia major (tdtm). methods: this case-control study was conducted 327 carrier couples for th...

background: in recent years, the success in management of thalassemic patients, has allowed for some previously unrecognized complications including renal abnormalities to emerge. this prospective study aimed to investigate kidney iron overload by means of mri t2* and also renal function based on laboratory tests for early markers of glomerular and tubular dysfunction among adult iranian transf...

background: hydroxyurea (hu) is a well known chemotherapeutic agent that has been used largely for various myeloproliferative diseases over the past 20 years. in β-thalassemia, the effect of hu is much less clear and remains controversial. this study was undertaken to describe the hematologic and clinical responses of thalassemia major and intermediate patients to hu treatment during 2 years. m...

Extramedullary hematopoiesis (EMH) is a physiological compensatory phenomenon occurring in many hemolytic anemias including thalassemia. Besides transfusion, radiotherapy, surgery or a combination of these modalities, hydroxyurea (HU) as an optimal treatment has been described occasionally. We described a case of beta-thalassemia major who has been on regular blood transfusion and developed EMH...

Background: Hydroxyurea (HU) is a well known chemotherapeutic agent that has been used largely for various myeloproliferative diseases over the past 20 years. In β-thalassemia, the effect of HU is much less clear and remains controversial. This study was undertaken to describe the hematologic and clinical responses of thalassemia major and intermediate patients to HU treatment during 2 years. M...

Introduction: Thalassemia is common in Iran. Appropriate therapy for this disease includes a regular blood transfusion and chelation therapy. However, patients will inevitably confront with side effects, particularly iron overloads in critical organ including heart, ductless glands and liver. This study tries to determine the prevalence of diabetes mellitus in transfusion dependent β thalassemi...